Belviq Gains FDA Approval For Weight Loss, But DEA Review Will Delay Launch
This article was originally published in The Pink Sheet Daily
Executive Summary
With a July 17 user fee date, Vivus’ obesity drug Qnexa could beat Arena Pharmaceuticals’ Belviq to the marketplace as lorcaserin awaits controlled substance scheduling by the Drug Enforcement Agency.
You may also be interested in...
Vivus Beefs Up Qsymia Efforts As Eisai Prepares To Launch Belviq
The obesity drug market will see substantial commercial investment in the second half of 2013. Vivus is planning its first DTC advertising for Qsymia and continuing its search for a big pharma partner, while Eisai/Arena have been cleared by the Drug Enforcement Agency to launch Belviq.
Arena Says Patient Programs Will Offset Belviq’s Premium Price For Some
The obesity pill will be priced at a slight premium to Vivus’ rival drug Qsymia, but Arena CEO says the amount patients will actually pay will vary based on coupon and rebate programs.
Orexigen Defines A Way To Get The Contrave PDUFA Clock Ticking
The summary report of an interim analysis of the ongoing LIGHT clinical trial evaluating the cardiovascular safety of the obesity medicine can form the basis of a resubmission of the Contrave NDA, the company announced, shaving some time off the PDUFA clock.